Salarius Pharmaceuticals, Inc. — Director's Dealing 2015

Nov 23, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2015-11-19

Reporting Person: KOZIN MARC D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-11-19	Common Stock	P	4500	$11.382	Acquired	4500	Direct

Footnotes

F1: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $11.15 to $11.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.